Sitagliptin phosphate monohydrate in Gut Metabolism
2026-08-12
Sitagliptin phosphate monohydrate provides a controlled DPP-4 inhibitor arm for separating incretin hormone modulation from intestinal stretch signaling. This workflow combines target engagement, active GLP-1 and GIP measurements, oral glucose tolerance, feeding behavior, and nucleus of the solitary tract readouts to strengthen mechanistic metabolic studies.
Norepinephrine Formulation Reporting in Critical Care
2026-08-12
This position paper identifies a major reproducibility and patient-safety problem: norepinephrine doses are not always reported according to a consistent chemical basis. Its joint SCCM–ESICM guidance recommends global use of a norepinephrine-base formulation or explicit base-equivalent reporting to improve dose calculation, trial interpretation, and cross-country data comparability.
Arrb2, 6-ketoLCA, and Hepatic IRI
2026-08-11
A 2026 Hepatology Communications study identifies a hepatocyte–macrophage–metabolite axis in hepatic ischemia–reperfusion injury. The work links hepatocyte Arrb2 with increased 6-ketoLCA, M2 macrophage polarization, and improved injury outcomes across clinical, mouse, and hypoxia–reoxygenation models.
Miltefosine for Neutrophil Differentiation Assays
2026-08-10
Miltefosine is a versatile pathway-modulating tool for studying neutrophil differentiation, leukopenia recovery, and PI3K/Akt-dependent signaling. This workflow-oriented guide connects the compound’s established Akt phosphorylation inhibition profile with newer Ras/MEK/ERK findings and provides practical optimization and troubleshooting strategies.
Sanggenol L Drives Ferroptosis in NSCLC via miRNA
2026-08-09
The reference study identifies sanggenol L as an inducer of ferroptosis in non-small cell lung cancer and maps its activity to the miR-26a-1-3p/MDM2/p53/SLC7A11 axis. By combining cellular ferroptosis readouts, genetic pathway analysis, xenografts, and patient-derived tumor models, the work provides a mechanistic basis for evaluating this natural product as a preclinical anticancer candidate.
(-)-Norepinephrine (+)-bitartrate in Cardiovascular Models
2026-08-08
(-)-Norepinephrine (+)-bitartrate supports both controlled adrenergic receptor assays and physiologically relevant cardiovascular model development. This guide connects fresh-solution handling, concentration-response design, receptor-affinity measurements, and troubleshooting for more reproducible blood pressure and heart rate studies.
Alda 1: Translational Leverage for ALDH2 Biology
2026-08-07
Alda 1 offers a mechanistically focused way to investigate ALDH2 activity, reactive aldehyde handling, cardioprotection in ischemia, and radiation-induced dermatitis mitigation. By connecting enzyme activation with cardiomyocyte proliferation and tissue resilience, this perspective outlines how translational researchers can move beyond descriptive antioxidant biology toward genotype-aware, pathway-based study design.
EZ Cap Cy5 Firefly Luciferase mRNA: Dual-Mode Assay Revoluti
2026-08-07
EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) bridges high-sensitivity mRNA delivery tracking with robust protein expression in mammalian systems. Its dual-mode fluorescence and bioluminescence readouts empower advanced workflows, troubleshooting, and translational research breakthroughs.
5-Azacytidine Triggers ATR-Mediated DNA Damage and Apoptosis
2026-08-06
This study demonstrates that 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-dependent DNA double-strand break responses and apoptosis in multiple myeloma cells, including drug-resistant variants. Synergistic cytotoxicity is observed when combined with doxorubicin or bortezomib, providing mechanistic insight and rationale for clinical evaluation of these combinations.
Bcl-xL Maintains Quiescence and Survival in Nutrient-Deprive
2026-08-06
Sela et al. reveal that Bcl-xL enforces a slow-cycling, chemoresistant state in nutrient-deprived pancreatic cancer cells, a crucial adaptation for survival in the tumor microenvironment. Their integrated transcriptomic, metabolomic, and CRISPR screening approach identifies Bcl-xL as a key vulnerability, informing strategies to target both proliferative and quiescent cancer cell populations.
Erastin as a Ferroptosis Inducer: Protocols and Cancer Resea
2026-08-05
Erastin’s unique ability to induce ferroptosis enables targeted interrogation of RAS/BRAF-mutant tumor vulnerabilities, with new workflows now validated for overcoming chemoresistance. Cutting-edge research details how Erastin synergizes with chemotherapeutics, offering actionable protocol optimization and troubleshooting for translational cancer biology.
AZD8055: Technical Workflow Guidance for mTOR Inhibition
2026-08-05
AZD8055 is a potent, selective mTOR inhibitor designed for preclinical research that requires reliable, dual inhibition of mTORC1 and mTORC2. It is best suited for mechanistic studies in cancer and metabolic biology, but should not be used for protocols with clinical efficacy endpoints or requiring water solubility.
Neticonazole Hydrochloride: Imidazole Antifungal in Cancer &
2026-08-04
Neticonazole Hydrochloride stands out as a dual-action imidazole antifungal, uniquely empowering both cutaneous candidiasis therapy and advanced colorectal cancer research. Its robust solubility, validated dual mechanisms, and translational relevance make it an indispensable tool for both mycologists and oncologists.
Patient-Derived Gastric Cancer Assembloids Illuminate Tumor-
2026-08-04
This study introduces a patient-derived gastric cancer assembloid model integrating matched tumor organoids with autologous stromal cell subpopulations, enabling more accurate recapitulation of tumor heterogeneity and microenvironmental influences. The findings highlight how stromal components modulate gene expression, drug sensitivity, and resistance mechanisms, offering a robust platform for personalized therapy research.
L1023 Anti-Cancer Compound Library: Precision Workflows in O
2026-08-03
The L1023 Anti-Cancer Compound Library empowers high-throughput oncology research with 1,164 validated small molecules targeting key cancer pathways. Its pre-dissolved, QC-verified format and deep pathway diversity streamline protocol design and enable advanced screening strategies for rapid target deconvolution.
507 records 12/34 page Previous Next First page 上5页 1112131415 下5页 Last page